| Autor: |
Marchenko NR; Research Institute of Eye Diseases, Moscow, Russia., Kasparova EA; Research Institute of Eye Diseases, Moscow, Russia., Budnikova EA; Research Institute of Eye Diseases, Moscow, Russia., Makarova MA; Research Institute of Eye Diseases, Moscow, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Vestnik oftalmologii [Vestn Oftalmol] 2021; Vol. 137 (6), pp. 142-148. |
| DOI: |
10.17116/oftalma2021137061142 |
| Abstrakt: |
Conjunctivitis may appear as the first symptom of the coronavirus infection (COVID-19). In isolated cases, the lesion of the conjunctiva evokes a systemic infectious process. Currently, the conjunctiva is not considered as an area of long-term reproduction of coronavirus, and its damage is caused by hyperproduction of pro-inflammatory cytokines (especially IL-6); development of iridocyclitis and keratoconjunctivitis is also possible. Most often, local corticosteroids are used to treat these processes, although their use requires caution due to the risk of activating secondary infection (herpetic bacterial, fungal), which often develops as a result of immunodeficiency caused both by COVID-19 and the massive corticosteroid and antibiotic therapy employed when the course of the disease is severe. The severe condition of patients, the lung ventilation, and the prone position all contribute to corneal erosions, exposure keratopathy, pseudomonas aeruginosa keratitis and angle-closure glaucoma attacks. The risk of transmission of coronavirus infection during keratoplasty is estimated as minimal. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
